P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

doi:10.1093/jnci/86.11.850

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

Journal of the National Cancer Institute - 1 Jun 1994

Schneider J, Rubio M P, Barbazán M J, Rodriguez-Escudero F J, Seizinger B R, Castresana J S

Abstract excerpt

BACKGROUND: Overexpression of P-glycoprotein has been associated with a worse prognosis for some groups of patients not receiving chemotherapy. Recently, it has been demonstrated that in vitro both c-Ha-Ras overexpression and mutant p53 overexpression do activate the MDR1 gene (also known as PGY1...

Topics

ATP Binding Cassette Transporter, Subfamily B, Member 1
Breast Neoplasms
Carrier Proteins
Endometrial Neoplasms
ErbB Receptors
Female
Gene Expression Regulation, Neoplastic
Genes, p53
Genital Neoplasms, Female
Humans
Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Membrane Glycoproteins

Mutation

Neoplasm Proteins

Polymerase Chain Reaction

Proto-Oncogene Proteins

Receptor, ErbB-2

Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 7910219
DOI: 10.1093/jnci/86.11.850

Genes

ERBB2
NCL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-7910219-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.PMID 7910219Read ↗

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.Semantic proximity Read ↗

Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.Semantic proximity Read ↗

Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.Semantic proximity Read ↗

[Analysis of p53, MDR-1, and GST-pi expression in endometrial carcinoma].Semantic proximity Read ↗

p53 tumor suppressor gene protein expression in cervical cancer: relationship to prognosis.Semantic proximity Read ↗

Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.Semantic proximity Read ↗

Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.Semantic proximity Read ↗

Overexpression and mutation of p53 in epithelial ovarian cancer.Semantic proximity Read ↗

Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.Semantic proximity Read ↗

Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.Semantic proximity Read ↗

Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels.Semantic proximity Read ↗

p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.